A
AEON Biopharma, Inc. (AEON)
ASE – Real Time Price. Currency in USD
0.88
-0.00 (-0.23%)
At close: May 12, 2026, 3:43 PM EDT
0.90
+0.02 (1.98%)
After-hours: May 12, 2026, 6:05 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.88
-0.00 (-0.23%)
At close: May 12, 2026, 3:43 PM EDT
0.90
+0.02 (1.98%)
After-hours: May 12, 2026, 6:05 PM EDT
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
| Name | Position |
|---|---|
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Mr. Alex Wilson | Chief Legal & Strategy Officer and Corporate Secretary |
| Mr. John A. Bencich M.B.A. | Chief Financial Officer |
| Mr. Robert Bancroft | President, CEO & Director |
| Ms. Jennifer Sy | Chief Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-29 | DEFA14A | aeon-20231109xdefa14a.htm |
| 2026-04-29 | DEF 14A | aeon-20260429xdef14a.htm |
| 2026-04-03 | 8-K | aeon-20260331x8k.htm |
| 2026-03-31 | S-8 | aeon-20231109xs8.htm |
| 2026-03-30 | 10-K | aeon-20251231x10k.htm |
| 2026-03-09 | 8-K | aeon-20260306x8k.htm |
| 2026-02-09 | S-3 | tm265572-1_s3.htm |
| 2026-01-21 | 8-K | aeon-20260121x8k.htm |
| 2026-01-12 | 8-K | aeon-20260112x8k.htm |
| 2025-12-29 | DEF 14A | aeon-20251229xdef14a.htm |